(HealthDay)—Lexatumumab, an agonistic, full human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2, is well tolerated and may lessen certain clinical symptoms in some pediatric ...
Oct 16, 2012
0
0
Using a novel surgical approach, it's possible to rebuild a functional lower jaw and mouth, and preserve a patient's ability to eat and speak after removing an invasive facial tumor, according to a new report from Henry Ford ...
Sep 7, 2012
0
0
(Medical Xpress) -- Scientists have found that a protein expressed by some cancers is a good predictor of how the cancer will respond to standard chemotherapy for osteosarcoma, the most common bone cancer in children. Knowing ...
Jul 3, 2012
0
0
